专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009149188A1 COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS 审中-公开
标题翻译：用于治疗炎症和纤维性疾病的化合物和方法
公开(公告)号：WO2009149188A1
公开(公告)日：2009-12-10
申请号：PCT/US2009/046136
申请日：2009-06-03
申请人： INTERMUNE, INC. , KOSSEN, Karl , SEIWERT, Scott, D. , SEREBRYANY, Vladimir , RUHRMUND, Donald , BEIGELMAN, Leonid , RAVEGLIA, Luca, Francesco Mario , VALLESE, Stefania , BIANCHI, Ivana , HU, Tao
发明人： KOSSEN, Karl , SEIWERT, Scott, D. , SEREBRYANY, Vladimir , RUHRMUND, Donald , BEIGELMAN, Leonid , RAVEGLIA, Luca, Francesco Mario , VALLESE, Stefania , BIANCHI, Ivana , HU, Tao
IPC分类号： A61K31/44 , C07D213/22
CPC分类号： C07D213/63 , C07D213/22 , C07D213/64 , C07D213/69 , C07D213/71 , C07D213/85 , C07D237/14 , C07D239/36 , C07D239/54 , C07D241/18 , C07D251/10 , C07D401/04 , C07D405/04 , C07D405/14 , C07D409/04 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/14 , C07D471/04
摘要： Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system.
摘要翻译：公开了用于治疗炎症和纤维化疾病的化合物和方法，包括用活性化合物调节应激活化蛋白激酶（SAPK）系统的方法，其中活性化合物表现出低的抑制p38MAPK的能力; 并且其中所述接触以对所述化合物抑制p38MAPK的抑制浓度低的SAPK调节浓度进行。还公开了吡非尼酮的衍生物和类似物，其可用于调节应激活化蛋白激酶（SAPK）系统。

2. 发明申请

WO2004004715A3 NOVEL DELTA OPIOID RECEPTOR LIGANDS 审中-公开
标题翻译：新西兰阿片类受体配偶
公开(公告)号：WO2004004715A3
公开(公告)日：2004-05-06
申请号：PCT/EP0307400
申请日：2003-07-08
申请人： GLAXOSMITHKLINE SPA , DONDIO GIULIO , MACECCHINI SILVIA , RAVEGLIA LUCA FRANCESCO
发明人： DONDIO GIULIO , MACECCHINI SILVIA , RAVEGLIA LUCA FRANCESCO
IPC分类号： A61K31/44 , C07D213/74 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/14 , A61K31/443 , A61K31/444
CPC分类号： C07D213/74 , A61K31/44 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/14
摘要： A method for the modulation of conditions associated with the delta opioid receptor, which method comprises the administration to the mammal in need thereof an effective or prophylactic amount of a compound of formula (I): wherein X, Y, Z, R1, and R2 are as defined in the specification; to compounds for use in such a method, to processes for their preparation, and to their use in medicine.
摘要翻译：调节与阿片样物质受体相关的病症的方法，该方法包括向有需要的哺乳动物施用有效或预防量的式（I）化合物：其中X，Y，Z，R 1和R 2 如规范中所定义; 用于这种方法的化合物，其制备方法及其在医药中的用途。

3. 发明申请

WO1997019928A1 SALTS OF QUINOLINE DERIVATIVES AS NK3 ANTAGONISTS 审中-公开
标题翻译：喹啉衍生物作为NK3拮抗剂的盐
公开(公告)号：WO1997019928A1
公开(公告)日：1997-06-05
申请号：PCT/EP1996005210
申请日：1996-11-22
申请人： SMITHKLINE BEECHAM S.P.A. , GIARDINA, Giuseppe, Arnaldo, Maria , FARINA, Carlo , GRUGNI, Mario , RAVEGLIA, Luca, Francesco
发明人： SMITHKLINE BEECHAM S.P.A.
IPC分类号： C07D215/52
CPC分类号： C07D215/52 , C07D215/50
摘要： A compound of formula (I) or a solvate thereof, characterised in that salt comprises a compound of formula (I) in anionic form and a salting cation; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine.
摘要翻译：式（I）化合物或其溶剂合物，其特征在于盐包含阴离子形式的式（I）化合物和盐析阳离子; 制备这种化合物的方法，含有这种化合物的药物组合物和这种化合物在医药中的用途。

4. 发明申请

WO1997019926A1 QUINOLINE-4-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS NEUROKININ 3 (NK-3)- AND NEUROKININ 2 (NK-2) RECEPTOR ANTAGONISTS. 审中-公开
标题翻译：喹啉-4-羧酰胺衍生物，其制备及其用作神经营养因子3（NK-3）和神经营养因子2（NK-2）受体拮抗剂。
公开(公告)号：WO1997019926A1
公开(公告)日：1997-06-05
申请号：PCT/EP1996005207
申请日：1996-11-22
申请人： SMITHKLINE BEECHAM S.P.A. , GIARDINA, Giuseppe, Arnaldo, Maria , GRUGNI, Mario , RAVEGLIA, Luca, Francesco , FARINA, Carlo
发明人： SMITHKLINE BEECHAM S.P.A.
IPC分类号： C07D215/52
CPC分类号： C07D231/12 , C07D215/52 , C07D233/56 , C07D249/08 , C07D401/12 , C07D487/04
摘要： A compound of formula (I), or a salt thereof, or a solvate thereof, wherein, Ar is an optionally substituted aryl or a C5-7 cycloalkdienyl group, or an optionally substituted single or fused ring aromatic heterocyclic group; R is C1-6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkylalkyl, optionally substituted phenyl or phenyl C1-6 alkyl, an optionally substituted five-membered heteroaromatic ring comprising up to four heteroatoms selected from O and N, hydroxy C1-6 alkyl, amino C1-6 alkyl, C1-6 alkylaminoalkyl, di C1-6 alkylaminoalkyl, C1-6 acylaminoalkyl, C1-6 alkoxyalkyl, C1-6 alkylcarbonyl, carboxy, C1-6 alkoxycarbonyl, C1-6 alkoxycarbonyl C1-6 alkyl, aminocarbonyl, C1-6 alkylaminocarbonyl, di C1-6 alkylaminocarbonyl, halogeno C1-6 alkyl; or R is a group -(CH2)p- wherein p is 2 or 3 which group forms a ring with a carbon atom of Ar; R1 represents hydrogen or up to four optional substituents selected from the list consisting of: C1-6 alkyl, C1-6 alkenyl, aryl, C1-6 alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, C1-6 alkoxycarbonyl, trifluoromethyl, acyloxy, phthalimido, amino or mono- and di-C1-6 alkylamino; R2 represents hydrogen, C1-6-alkyl, hydroxy, halogen, cyano, amino, mono- or di-C1-6-alkylamino, alkylsulphonylamino, mono- or di-C1-6-alkanoylamino wherein any alkyl group is optionally substituted with an amino group or with a mono- or di-alkylamino group, or R2 is a moiety -X-(CH2)n-Y wherein X is a bond or -O- and n is an integer in the range of from 1 to 5 providing that when X is O-n is only an integer from 2 to 5 and Y represents a group NY1Y2 wherein Y1 and Y2 are independently selected from hydrogen, C1-6-alkyl, C1-6-alkenyl, aryl or aryl-C1-6-alkyl or Y is hydroxy, halogen or an optionally substituted N-linked single or fused ring, heterocyclic group, R3 is branched or linear C1-6 alkyl, C3-7 cycloalkyl, C4-7 cycloalkylalkyl, optionally substituted aryl, or an optionally substituted single or fused ring aromatic heterocyclic group; and R4 represents hydrogen or C1-6 alkyl.
摘要翻译：式（I）化合物或其盐或其溶剂合物，其中Ar为任选取代的芳基或C 5-7环二烯基，或任选取代的单环或稠环芳族杂环基; R为C 1-6烷基，C 3-7环烷基，C 3-7环烷基烷基，任选取代的苯基或苯基C 1-6烷基，任选取代的五元杂芳环，其包含至多四个选自O和N的杂原子，羟基C 1-6 烷基，氨基C 1-6烷基，C 1-6烷基氨基烷基，二C 1-6烷基氨基烷基，C 1-6酰基氨基烷基，C 1-6烷氧基烷基，C 1-6烷基羰基，羧基，C 1-6烷氧基羰基，C 1-6烷氧基羰基C 1-6烷基，氨基羰基，C 1-6烷基氨基羰基，二C 1-6烷基氨基羰基，卤代C 1-6烷基; 或R为基团 - （CH 2）p - ，其中p为2或3，该基团与Ar的碳原子形成环; R 1表示氢或至多四个选自以下的任选取代基：C 1-6烷基，C 1-6烯基，芳基，C 1-6烷氧基，羟基，卤素，硝基，氰基，羧基，甲酰氨基，磺酰氨基，C 1-6 烷氧基羰基，三氟甲基，酰氧基，苯二甲酰亚氨基，氨基或单 - 和二-C 1-6烷基氨基; R 2表示氢，C 1-6 - 烷基，羟基，卤素，氰基，氨基，单或二-C 1-6 - 烷基氨基，烷基磺酰基氨基，单 - 或二-C 1-6 - 烷酰基氨基，其中任何烷基任选被氨基或单 - 或二 - 烷基氨基，或R2是部分-X-（CH2）nY，其中X是一个键或-O-，n是1至5的整数，条件是当 X为“On”仅为2至5的整数，Y表示NY1Y2基团，其中Y 1和Y 2独立地选自氢，C 1-6 - 烷基，C 1-6 - 烯基，芳基或芳基-C 1-6 - 烷基或Y 是羟基，卤素或任选取代的N-连接的单或稠环，杂环基，R 3是支链或直链C 1-6烷基，C 3-7环烷基，C 4-7环烷基烷基，任选取代的芳基，或任选取代的单或稠合环芳族杂环基; 且R 4表示氢或C 1-6烷基。

5. 发明申请

WO1996002509A1 QUINOLINE DERIVATIVES AS NK3 ANTAGONISTS 审中-公开
标题翻译：喹啉衍生物作为NK3拮抗剂
公开(公告)号：WO1996002509A1
公开(公告)日：1996-02-01
申请号：PCT/EP1995002638
申请日：1995-07-06
申请人： SMITHKLINE BEECHAM FARMACEUTICI S.P.A. , FARINA, Carlo , GIARDINA, Giuseppe, Arnaldo, Maria , GRUGNI, Mario , RAVEGLIA, Luca, Francesco
发明人： SMITHKLINE BEECHAM FARMACEUTICI S.P.A.
IPC分类号： C07D215/52
CPC分类号： C07D401/12 , C07D215/20 , C07D215/52
摘要： NK3 receptor antagonists of formula (I) are useful in the treatment of pulmonary and CNS disorders.
摘要翻译：式（I）的NK3受体拮抗剂可用于治疗肺和CNS疾病。

6. 发明申请

WO2005054190A1 3-AMINOPYRROLIDONE DERIVATIVES 审中-公开
标题翻译： 3-氨基吡咯烷酮衍生物
公开(公告)号：WO2005054190A1
公开(公告)日：2005-06-16
申请号：PCT/EP2004/012957
申请日：2004-11-16
申请人： NEWRON PHARMACEUTICALS S.p.A. , THALER, Florian , SABIDO DAVID, Cibele, Maria , MAESTRONI, Sara , RAVEGLIA, Luca, Francesco , SALVATI, Patricia
发明人： THALER, Florian , SABIDO DAVID, Cibele, Maria , MAESTRONI, Sara , RAVEGLIA, Luca, Francesco , SALVATI, Patricia
IPC分类号： C07D207/273
CPC分类号： C07D207/273 , A61K31/4015 , A61K31/4412 , A61K31/55 , C07D211/76
摘要： This invention is related to compounds and use of 3-aminopyrrolidone derivatives and analogues of the following general formula (I), wherein m is an integer from 1 to 3; X is methylene, oxygen, sulphur or a NR 6 group; R 1 is a straight or branched C 1 -C 8 alkyl or C 3 -C 8 alkenylene or C 3 -C 8 alkynylene chain, optionally substituted with CF 3 , phenyl, phenoxy or naphthyl, or phenyl the aromatic rings optionally substituted by one or more C 1 -C 4 alkyl, halogens, trifluoromethyl, hydroxy or C 1 -C 4 alkoxy groups; R 2 , R 3 are independently hydrogen, a C 1 -C 3 alkyl chain, halogen, trifluoromethyl, hydroxy or C 1 -C 4 alkoxy groups; R 4 , R 5 , R 6 are independently hydrogen or C 1 -C 6 alkyl; and the pharmaceutically acceptable salts thereof that are active as sodium and/or calcium channel modulators and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.
摘要翻译：本发明涉及以下通式（I）的3-氨基吡咯烷酮衍生物和类似物的化合物和用途，其中m为1至3的整数; X是亚甲基，氧，硫或NR 6基团; R 1是任选被CF 3，苯基，苯氧基或萘基取代的直链或支链C 1 -C 8烷基或C 3 -C 8亚烯基或C 3 -C 8亚炔基链，或苯基，任选被一个或多个C 1 -C 4 烷基，卤素，三氟甲基，羟基或C 1 -C 4烷氧基; R 2，R 3独立地是氢，C 1 -C 3烷基链，卤素，三氟甲基，羟基或C 1 -C 4烷氧基; R 4，R 5，R 6独立地是氢或C 1 -C 6烷基; 和其药学上可接受的盐，其作为钠和/或钙通道调节剂是有活性的，因此可用于预防，缓解和治愈广泛范围的病理学，包括但不限于心血管，炎症，眼科，泌尿，代谢和胃肠道疾病其中上述机制被描述为发挥病理作用。

7. 发明申请

WO2004004715A2 NOVEL METHOD & COMPOUNDS 审中-公开
标题翻译：新方法与化合物
公开(公告)号：WO2004004715A2
公开(公告)日：2004-01-15
申请号：PCT/EP2003/007400
申请日：2003-07-08
申请人： GLAXOSMITHKLINE SPA , DONDIO, Giulio , MACECCHINI, Silvia , RAVEGLIA, Luca, Francesco
发明人： DONDIO, Giulio , MACECCHINI, Silvia , RAVEGLIA, Luca, Francesco
IPC分类号： A61K31/44
CPC分类号： C07D213/74 , A61K31/44 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/14
摘要： A method for the modulation of conditions associated with the delta opioid receptor, which method comprises the administration to the mammal in need thereof an effective or prophylactic amount of a compound of formula (I): (I)wherein X, Y, Z, R1, and R2 are as defined in the specification; to compounds for use in such a method, to processes for their preparation, and to their use in medicine.
摘要翻译：用于调节与阿片样物质受体有关的病症的方法，该方法包括向有需要的哺乳动物施用有效或预防量的式（I）化合物：（I）其中X，Y，Z，R 1 ，和R2如说明书中所定义; 用于这种方法的化合物，其制备方法及其在医药中的用途。

8. 发明申请

WO1997021680A1 QUINOLINE DERIVATIVES 审中-公开
标题翻译：喹啉衍生物
公开(公告)号：WO1997021680A1
公开(公告)日：1997-06-19
申请号：PCT/EP1996005203
申请日：1996-11-22
申请人： SMITHKLINE BEECHAM S.P.A. , GIARDINA, Giuseppe, Arnaldo, Maria , GRUGNI, Mario , RAVEGLIA, Luca, Francesco , FARINO, Carlo
发明人： SMITHKLINE BEECHAM S.P.A.
IPC分类号： C07D215/52
CPC分类号： C07D215/52
摘要： A compound, or a solvate or a salt thereof, of formula (I), wherein, Ar is an optionally substituted aryl or a C5-7 cycloalkdienyl group, or an optionally substituted single or fused ring aromatic heterocyclic group; R, R1, R2 and R3 are as defined in the description; a process for the preparation of such a compound, a pharmaceutical composition containing such a compound or composition in medicine.
摘要翻译：式（I）的化合物或其溶剂合物或其盐，其中Ar为任选取代的芳基或C 5-7环二烯基，或任选取代的单环或稠环芳族杂环基; R，R1，R2和R3如说明书中所定义; 制备这种化合物的方法，在药物中含有这种化合物或组合物的药物组合物。

9. 发明申请

WO1997019927A1 QUINOLINE DERIVATIVES AS NK3 ANTAGONISTS 审中-公开
标题翻译：喹啉衍生物作为NK3拮抗剂
公开(公告)号：WO1997019927A1
公开(公告)日：1997-06-05
申请号：PCT/EP1996005209
申请日：1996-11-22
申请人： SMITHKLINE BEECHAM S.P.A. , GIARDINA, Giuseppe, Arnaldo, Maria , FARINA, Carlo , GRUGNI, Mario , RAVEGLIA, Luca, Francesco
发明人： SMITHKLINE BEECHAM S.P.A.
IPC分类号： C07D215/52
CPC分类号： C07D417/04 , A61K31/47 , A61K31/4709 , A61K31/473 , C07D215/52 , C07D221/18 , C07D401/04 , C07D401/12 , C07D405/04 , C07D409/04 , C07D409/12 , Y10S514/912
摘要： A method for the treatment and/or prophylaxis of conditions characterized by overstimulation of the tachykinin receptors, which method comprises the administration to a mammal in need thereof of an effective, non-toxic, pharmaceutically acceptable amount of a compound of formula (I), or a pharmaceutically acceptable solvate thereof, or a pharmaceutically acceptable salt thereof, wherein: Ar is an optionally substituted phenyl, naphthyl or C5-7 cycloalkdienyl group, or an optionally substituted single or fused ring heterocyclic group, having aromatic character, containing from 5 to 12 ring atoms and comprising up to four heteroatoms in the or each ring selected from S, O, N; R is linear or branched C1-8alkyl, C3-7cycloalkyl, C4-7cycloalkylalkyl, optionally substituted phenyl or phenyl C1-6alkyl, an optionally substituted five-membered heteroaromatic ring comprising up to four heteroatoms selected from O and N, hydroxy C1-6alkyl, amino C1-6alkyl, C1-6alkylaminoalkyl, di C1-6alkylaminoalkyl, C1-6acylaminoalkkyl, C1-6alkoxyalkyl, C1-6alkylcarbonyl, carboxy, C1-6alkoxycarbonyl, C1-6alkoxycarbonyl, C1-6alkyl, aminocarbonyl, C1-6alkylaminocarbonyl, di C1-6alkylaminocarbonyl; halogeno C1-6alkyl; or is a group -(CH2)p- when cyclized onto Ar, where p is 2 or 3. R1 and R2, which may be the same or different, are independently hydrogen or C1-6 linear or branched alkyl, or together form a -(CH2)n- group in which n represents 3, 4 or 5; or R1 together with R forms a group -(CH2)q-, in which q is 2, 3, 4 or 5; R3 and R4, which may be the same or different, are independently hydrogen, C1-6 linear or branched alkyl, C1-6alkenyl, aryl, C1-6alkoxy, hydroxy, halogen, nitro, cyano, carboxy, carboxamido, sulphonamido, C1-6alkoxycarbonyl, trifluoromethyl, acyloxy, phthalimido, amino, mono- and di-C1-6alkylamino, -O(CH2)r-NT2, in which r is 2, 3 or 4 and T is hydrogen or C1-6alkyl or it forms with the adjacent nitrogen a group (a) or (b), in which V and V1 are independently hydrogen or oxygen and u is 0, 1 or 2; -O(CH2)s-OW in which s is 2, 3 or 4 and W is hydrogen or C1-6alkyl; hydroxyalkyl, aminoalkyl, mono- or di-alkylaminoalkyl, acylamino, alkylsulphonylamino, aminoacylamino, mono- or di-alkylaminoacylamino; with up to four R3 substituents being present in the quinoline nucleus; or R4 is a group -(CH2)t- when cyclized onto R5 as aryl, in which t is 1, 2 or 3; R5 is branched or linear C1-6alkyl, C3-7cycloalkyl, C4-7cycloalkylalkyl, optionally substituted aryl, or an optionally substituted single or fused ring heterocyclic group, having aromatic character, containing from 5 to 12 ring atoms and comprising up to four heteroatoms in the or each ring selected from S, O, N; X is O, S, or N-CN.
摘要翻译：用于治疗和/或预防速激肽受体过度刺激的病症的方法，该方法包括向有需要的哺乳动物施用有效，无毒的药学上可接受量的式（I）化合物，或其药学上可接受的溶剂合物或其药学上可接受的盐，其中：Ar是任选取代的苯基，萘基或C 5-7环二烯基，或具有芳族特征的任选取代的单或稠环杂环基，其含有5至 12个环原子，并且在选自S，O，N的或每个环中包含至多四个杂原子; R为直链或支链C 1-8烷基，C 3-7环烷基，C 4-7环烷基烷基，任选取代的苯基或苯基C 1-6烷基，任选取代的五元杂芳环，其包含至多四个选自O和N的杂原子，羟基C 1-6烷基，氨基羰基，C 1-6烷基氨基羰基，C 1-6烷基氨基烷基，C 1-6烷基氨基烷基，C 1-6烷氧基烷基，C 1-6烷基羰基，羧基，C 1-6烷氧基羰基，C 1-6烷氧基羰基，C 1-6烷基，氨基羰基，C 1-6烷基氨基羰基， ; 卤代C 1-6烷基; 或者当环化为Ar时为 - （CH 2）p - ，其中p为2或3.可以相同或不同的R 1和R 2独立地为氢或C 1-6直链或支链烷基，或一起形成 - （CH 2）n - 基，其中n表示3,4或5; 或R 1与R一起形成基团 - （CH 2）q - ，其中q为2,3,4或5; R 3和R 4可以相同或不同，独立地为氢，C 1-6直链或支链烷基，C 1-6烯基，芳基，C 1-6烷氧基，羟基，卤素，硝基，氰基，羧基，甲酰氨基，磺酰氨基， 6-烷氧基羰基，三氟甲基，酰氧基，苯二甲酰亚氨基，氨基，单-C 1-6烷基氨基，-O（CH 2）r-NT 2，其中r为2,3或4，T为氢或C 1-6烷基，相邻的氮a（a）或（b），其中V和V1独立地是氢或氧，u是0,1或2; -O（CH2）s-OW，其中s为2,3或4，W为氢或C1-6烷基; 羟基烷基，氨基烷基，一或二烷基氨基烷基，酰氨基，烷基磺酰基氨基，氨酰基氨基，单或二烷基氨基酰氨基; 在喹啉核中存在多达四个R 3取代基; 或R 4为 - 作为芳基环化为R5的基团 - （CH 2）t - ，其中t为1,2或3; R5是具有芳族特征的支链或直链C 1-6烷基，C 3-7环烷基，C 4-7环烷基烷基，任选取代的芳基或任选取代的单或稠环杂环基，其含有5至12个环原子并且包含至多四个杂原子所述或每个环选自S，O，N; X是O，S或N-CN。

10. 发明申请

WO1995032948A1 QUINOLINE DERIVATIVES AS TACHYKININ NK3 RECEPTOR ANTAGONISTS 审中-公开
标题翻译：喹啉衍生物作为TACHYKININ NK3受体拮抗剂
公开(公告)号：WO1995032948A1
公开(公告)日：1995-12-07
申请号：PCT/EP1995002000
申请日：1995-05-23
申请人： SMITHKLINE BEECHAM FARMACEUTICI S.P.A. , FARINA, Carlo , GIARDINA, Giuseppe, Arnaldo, Maria , GRUGNI, Mario , RAVEGLIA, Luca, Francesco
发明人： SMITHKLINE BEECHAM FARMACEUTICI S.P.A.
IPC分类号： C07D215/52
CPC分类号： C04B35/632 , A61K31/00 , A61K31/4709 , C07D215/52 , C07D221/18 , C07D401/04 , C07D401/12 , C07D405/04 , C07D409/04 , C07D409/12 , C07D417/04
摘要： NK3 receptor antagonists of formula (I) are useful in treating inter alia pulmonary disorders, CNS disorders and neurodegenerative disorders.
摘要翻译：式（I）的NK3受体拮抗剂可用于治疗肺功能紊乱，中枢神经系统疾病和神经变性疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式